← Back to Search

CAR T-cell Therapy

Adoptive Cell Therapy for Melanoma (ACT Trial)

Phase 1
Recruiting
Research Sponsored by AgonOx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1, 2, 4, 8, and 12 weeks after cell infusion, then per pi discretion
Awards & highlights

Summary

This trial will look at using selected autologous cells from a patient's tumor to treat late-stage cancer. The cells are expanded, then delivered intravenously. It is hoped they will be more effective in treating cancer.

Who is the study for?
Adults over 18 with advanced solid tumors that are metastatic or unresectable, and have progressed after standard therapy. They must have a tumor large enough for cell extraction and meet specific blood, liver, and kidney function criteria. Women of childbearing age must avoid pregnancy during the trial.
What is being tested?
The study tests adoptive cell therapy using autologous CD8+ TIL (tumor infiltrating lymphocytes) selected for their cancer-fighting potential in patients with various solid tumors. Patients will receive an infusion of these cells along with low-dose IL-2 to enhance treatment efficacy.
What are the potential side effects?
Potential side effects may include reactions related to immune system activation such as inflammation in different body parts, fatigue, flu-like symptoms due to IL-2 administration, and complications from intravenous infusions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks after cell infusion, then per pi discretion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks after cell infusion, then per pi discretion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety of DP CD8 TIL
Secondary study objectives
Compare persistence of DP CD8 TIL and DP CD8 TIL KD in peripheral blood
Efficacy of DP CD8 TIL

Trial Design

2Treatment groups
Experimental Treatment
Group I: DP CD8 TIL KDExperimental Treatment2 Interventions
Adoptive Cell Transfer of tumor infiltrating lymphocytes that were selected for tumor reactivity by the expression of cell surface proteins CD39 and CD103 and expanded in vitro in the presence of PH-762, a silencing RNA that reduces the expression of the checkpoint inhibitor PD-1. A suspension of 1-40 billion cells will be delivered one time by intravenous infusion.
Group II: DP CD8 TILExperimental Treatment2 Interventions
Adoptive Cell Transfer of tumor infiltrating lymphocytes that were selected for tumor reactivity by the expression of cell surface proteins CD39 an CD103 and expanded in vitro. A suspension of 1-40 billion cells will be delivered one time by intravenous infusion.

Find a Location

Who is running the clinical trial?

Phio Pharmaceuticals Inc.Industry Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
AgonOx, Inc.Lead Sponsor
Phio Pharmaceuticals Corp.UNKNOWN

Media Library

Urogenital Cancer Research Study Groups: DP CD8 TIL, DP CD8 TIL KD
Urogenital Cancer Clinical Trial 2023: DP CD8 TIL Highlights & Side Effects. Trial Name: NCT05902520 — Phase 1
DP CD8 TIL (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05902520 — Phase 1
~5 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top